Profile data is unavailable for this security.
Mergers & acquisitions
Acquired company | NOVO B:CPH since announced | Transaction value |
---|---|---|
Cardior Pharmaceuticals GmbH | 2.72% | 1.11bn |
Catalent Inc-Manufacturing Sites Portfolio(3) | 16.62% | -- |
Elan Drug Technologies (DNU>16Sep2011 now 01781A) | 35.65% | 92.42m |
Embark Biotech ApS | 40.96% | 16.22m |
Inversago Pharma Inc | 44.26% | 1.08bn |
Data delayed at least 15 minutes, as of Jul 22 2024 12:41 BST.